South Texas Accelerated Research Therapeutics (START) Madrid - CIOCC
South Texas Accelerated Research Therapeutics (START) Madrid - CIOCC
Madrid, Spain4 results ยท Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A Study of Patritumab Deruxtecan (HER3-DXd) in Combination With Trastuzumab Deruxtecan (T-DXd) in Participants With HR-Positive, HER2-Low or HER2-Ultralow Unresectable or Metastatic Breast Cancer | Neoplasms by Site, Skin and Connective Tissue Diseases, breast disorder, breast neoplasm, neoplasm, skin disorder | Recruiting | Phase 1 / Phase 2 | 2026-10-01 | NCT07701941 | |
| Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies | Brain Metastases, Digestive System Diseases, Digestive System Neoplasms, Head and Neck Neoplasms, Hemic and Lymphatic Diseases, Neoplasms by Site, Thoracic Neoplasms, brain disorder, bronchial neoplasm, bronchogenic carcinoma, central nervous system cancer, central nervous system disorder, colonic disorder, colorectal cancer, colorectal neoplasm, digestive system disorder, digestive system neoplasm, endocrine system disorder, histiocytosis, intestinal disorder, lung disorder, lung neoplasm, lymphatic system disorder, malignant endocrine neoplasm, neoplasm, nervous system disorder, non-small cell lung carcinoma, rectal disorder, respiratory system disorder, respiratory tract neoplasm, thyroid gland carcinoma, thyroid gland disorder, thyroid tumor | Recruiting | Phase 1 / Phase 2 | 2026-09-16 | NCT05786924 | |
| FORAGER-1: A Study of Vepugratinib (LY3866288; LOXO-435) in Participants With Cancer With a Change in a Gene Called FGFR3 | Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Male Urogenital Diseases, Neoplasm Metastasis, Neoplasms by Histologic Type, Neoplasms by Site, Neoplastic Processes, Non-Muscle Invasive Bladder Neoplasms, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Urogenital Diseases, Urogenital Neoplasms, benign urinary system neoplasm, carcinoma, epithelial neoplasm, neoplasm, ureter cancer, ureteral disorder, urinary bladder disorder, urinary bladder neoplasm, urinary system disorder | Recruiting | Phase 1 | 2026-08-20 | NCT05614739 | |
| A Study of HFB200603 as a Single Agent and in Combination With Tislelizumab in Adult Patients With Advanced Solid Tumors | Digestive System Diseases, Digestive System Neoplasms, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Male Urogenital Diseases, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, Skin and Connective Tissue Diseases, Thoracic Neoplasms, Urogenital Diseases, Urogenital Neoplasms, adenocarcinoma, benign urinary system neoplasm, bronchial neoplasm, bronchogenic carcinoma, carcinoma, colonic disorder, colorectal cancer, colorectal neoplasm, digestive system disorder, digestive system neoplasm, epithelial neoplasm, gastric cancer, gastric neoplasm, intestinal disorder, kidney cancer, kidney disorder, lung disorder, lung neoplasm, melanocytic neoplasm, melanoma, neoplasm, neuroendocrine neoplasm, non-small cell lung carcinoma, primitive neuroectodermal tumor, rectal disorder, renal cell carcinoma, respiratory system disorder, respiratory tract neoplasm, skin disorder, skin neoplasm, stomach disorder, urinary system disorder | Active, not recruiting | Phase 1 | 2026-06-08 | NCT05789069 |